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432A Phase I Study in Adults of Clofarabine Combined with
High-Dose Melphalan as Reduced-Intensity
Conditioning for Allogeneic Transplantation
Mark H. Kirschbaum,1 Anthony S. Stein,1 Leslie Popplewell,1 Maria Delioukina,1
Robert Chen,1 Ryotaro Nakamura,1 David Snyder,1 Joel Conrad,2
Simon F. Lacey,3 Paul Frankel,4 Andrew Dagis,4 Auayporn Nademanee,1 Stephen J. Forman1Clofarabine is a novel purine nucleoside analog with immunosuppressive and antileukemia activity. We per-
formed a phase I study of the combination of clofarabine plus melphalan as a reduced-intensity conditioning
regimen for allogeneic stem cell transplantation in patients with acute myelogenous leukemia. Patients over
age 18 in complete remission or with active disease (up to 50%marrow blasts) who had a matched related or
unrelated donor were eligible. The conditioning regimen consisted of escalating doses of clofarabine plus
melphalan, followed by allogeneic stem cell transplantation. Sixteen patients (median age, 63 years) were
treated at 3 dose levels; 4 of these patients had primary induction failure, and 3 were in first relapse. One
patient at dose level 2 and 1 patient at dose level 3 died of multiorgan toxicity; no other dose-limiting tox-
icities were seen. All other patients at both doses of clofarabine studied demonstrated complete engraftment
by day 30, with a median time to absolute neutrophil count recovery of 14 days, and 16 days for platelet re-
covery.With a median follow-up of 17 months, only 2 patients relapsed, and 4 patients died. Clofarabine plus
melphalan at dose level 2 is a well-tolerated conditioning regimen with activity in patients with advanced
acute myelogenous leukemia.
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Allogeneic stem cell transplantation remains the
only curative treatment modality for hematologic malig-
nancies, such as acute myelogenous leukemia (AML),
acute lymphoblastic leukemia (ALL), and myelodys-
plastic syndrome (MDS) [1-3]. Conditioning regimens
for allogeneic transplantation serve 2 purposes: (1)
maximal immunosuppression to prevent transplant
rejection and (2) killing of any remaining tumor cells.
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/$36.00
6/j.bbmt.2011.07.017over time, with the recognition that immuno-
suppression may be more important than tumor kill by
chemotherapy, given that a critical component of
allogeneic transplantation is the graft-versus-tumor
effect [4,5]. This prompted development of the first
reduced-intensity regimens, replacing the toxic alkylat-
ing agent cyclophosphamide with the purine nucleoside
antimetabolite fludarabine, which is a potent immuno-
suppressant with a substantially milder toxicity profile
[6]. The success of these reduced-intensity regimens in
terms of lower toxicity, with apparently equal efficacy,
at least in the case of chronic myelogenous leukemia
and AML in patients .50 years old [7], has allowed
the benefits of transplantation to be extended to groups
that were previously excluded [8-10]. However,
fludarabine is not an active agent against leukemias or
MDS; thus, devising a reduced-intensity regimen with
greater antitumor efficacy may be beneficial.
Clofarabine is a rationally designed, second-
generation purine nucleoside analog. The double-
halogen strategy confers resistance to adenosine
deaminase while increasing acid stability and bio-
availability, in part through more rapid membrane
transport [11]. Clofarabine is more efficient than flu-
darabine at inhibiting DNA polymerase A, inhibiting
Biol Blood Marrow Transplant 18:432-440, 2012 433Phase I Clofarabine/Melphalan Allo Transplantribonucleotide reductase, and disrupting mitochon-
drial function, leading to apoptosis via recruitment of
APAF-1 [12]. This latter activity may explain the in-
creased killing of nondividing lymphocytes [13,14],
an advantage that theoretically will decrease the
likelihood of rejection in the allogeneic setting and
perhaps augment the graft-versus-tumor effect of the
donor graft.
The use of clofarabine in place of fludarabine in
a reduced-intensity conditioning regimenmay provide
enhanced immunosuppression as well as a likely
increased antileukemia effect. For this reason, we pro-
posed a phase I dose escalation study of clofarabine
combined with high-dose melphalan followed by allo-
geneic stem cell reinfusion on day 0.Stem Cells
Infused-9 -8 -7 -6 -5 -4 -3
Clofarabine:
30” IV infusion daily 
Mel:
30” IV
-2 -1
Timeline (Days Pretransplantation)
GVHD
prophylaxis
Figure 1. Treatment schema. Treatments are shown on the timeline
spanning the days before stem cell infusion on day 0. Mel, melphalan.METHODS
Patient Eligibility
Patients $18 years of age with AML, ALL, or
MDS in first complete remission (CR1), in second
complete remission (CR2), in relapse, or with induc-
tion failure (ie, with no more than 50% marrow blasts
at the time of enrollment) who were considered ineli-
gible for standard transplantation regimens or at
high risk for relapse by the attending physician were
eligible for this study. To be treated on this protocol,
patients had to have a 6/6 match in an HLA-matched
sibling or a 10/10-matched unrelated donor (ie, allele-
level matched at HLA-A, -B, -C, -DRB1, and -DQB1)
from either granulocyte-colony stimulating factor
mobilized peripheral blood stem cells or harvested
bone marrow.
Other eligibility criteria included a Karnofsky per-
formance status score of $50% and a minimum of
4 weeks elapsed since completion of the previous che-
motherapy regimen. Patients who had undergone pre-
vious autologous transplantation were eligible if they
were at least 100 days posttransplantation and without
active cytomegalovirus and fungal infections. Patients
may have received previous radiation therapy as part
of a previous transplantation conditioning regimen,
which must have been completed at least 100 days
before starting the study regimen. A pretreatment
calculated creatinine clearance (absolute value) of $60
mL/minute or a serum creatinine value of\1.5 times
the upper limit of normal, a serum bilirubin level
#2.0 mg/dL, serum glutamic oxaloacetic transaminase
and serum glutamic pyruvic transaminase #2.5 times
the institutional upper limits of normal, an ejection
fraction of $50% measured by echocardiography or
multigated acquisition scan, and lung CO diffusion ca-
pacity or forced expiratory volume in 1 second$40%of
predicted value was required. Patients with suspected or
proven central nervous system (CNS) leukemia; pa-
tients with uncontrolled concurrent illness including,but not limited to, ongoing or active or poorly con-
trolled infection, symptomatic congestive heart failure,
unstable angina pectoris, cardiac arrhythmia, poorly
controlled pulmonary disease, or psychiatric illness/
social situations that would limit compliance with study
requirements; pregnant women; and HIV-positive
patients were excluded from this study.
Treatment Plan
Eligible patients were treated with a conditioning
regimen consisting of clofarabine and melphalan
beginning on day 29 and continuing until day 24
(Figure 1). Clofarabine was administered at the appro-
priate dose level (dose level 1, 30 mg/m2; dose levels
2 and 3, 40 mg/m2) daily on day 29 to day -5, infused
i.v. over 30 minutes. Melphalan (dose levels 1 and 2,
100mg/m2; dose level 3, 140mg/m2) was administered
i.v. over 30minutes on day24. On day 0, patients were
infused with allogeneic stem cells. Graft-versus-host
disease (GVHD) prophylaxis for the first 3 patients
(all at dose level 1) was with cyclosporine and myco-
phenolate mofetil; however, this regimen was replaced
with the combination of tacrolimus and sirolimus as
the standard of care at City ofHope, and thus the study
protocol was changed such that all subsequent patients
received tacrolimus 0.02 mg/kg/day continuous i.v. in-
fusion beginning on day 23 and sirolimus adminis-
tered as a 12-mg oral loading dose on day 23,
followed by a 4-mg oral single morning daily dose (tar-
get serum level, 3-12 ng/mL by high-performance liq-
uid chromatography). Management of sirolimus and
tacrolimus levels was in accordance with standard
City of Hope protocol [15]. In the absence of acute
GVHD, all patients began tapering of GVHDprophy-
laxis at 3 months, with discontinuation by 6 months.
Patient Evaluation
The pretransplantation workup included history
and physical examination, vital signs (temperature,
pulse, respiration, and blood pressure), height and
weight, Karnofsky performance status, ABO/Rh typ-
ing, direct Coombs test, comprehensive metabolic
panel, hepatitis panel, cytomegalovirus and herpes
simplex titers, HIV antibody, prothrombin time and
partial thromboplastin time, urinalysis, quantitative
immunoglobulin levels, peripheral blood mononu-
clear cell immunophenotyping, B2 microglobulin,
pulmonary function tests with lung CO diffusion
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electrocardiography, echocardiography or multigated
acquisition scan, chest x-ray, urine pregnancy test
(female subjects only), 24-hour urine creatinine clear-
ance, and thyroid panel (free T4 and thyroid-
stimulating hormone).
Bonemarrow aspirate and biopsy plus cytogenetics
were required within 7 days before the start of treat-
ment. Lumbar puncture for patients at high risk for
CNS involvement was required by protocol for
patients with French-American-British subtype M4,
M4eo, or M5; patients with a white blood cell
(WBC) count .50,000/mL at diagnosis; and patients
with cutaneous involvement.Study Design
This was a phase I dose-escalation study where the
primary objective was to determine the recommended
phase II dose of clofarabine when used in conjunction
with melphalan as a conditioning regimen for alloge-
neic stem cell transplantation in patients who were
not eligible for standard transplantation studies and
met the specified eligibility requirements. The 3 dos-
age levels tested varied the dosage of clofarabine and/
or melphalan, as detailed in Table 1.
The objectives of this study were (1) to determine
the maximum tolerated dose and evaluate the toxicities
of the combination of clofarabine plus high-dose mel-
phalan as a conditioning regimen for allogeneic trans-
plantation; (2) to assess the efficacy of the combination
of clofarabine plus high-dose melphalan in facilitating
engraftment in HLA-matched allogeneic transplan-
tation; and (3) to evaluate engraftment, immune recon-
stitution, and therapeutic outcomes.
Two types of toxicities were considered: dose-
limiting toxicity (DLT) and graft failure, or rejection
(GR). GR was defined as an absolute neutrophil count
(ANC) of\500 (0.5  109/L) by 28 days posttrans-
plantation with no evidence of other causes, such as
recurrent progressive leukemia, renal failure, chronic
bleeding, severe infection, drug-induced cytopenia,
or development of new hematologic problems (nutri-
tional or otherwise). DLT in a given patient is defined
as any regimen-related grade III/IV toxicity according
to the Bearman scale [16]. To be evaluable for toxicity,
a patient must start treatment and be observed for at
least 4 weeks (or until after engraftment, whichever is
longer) after completion of transplantation, or have
experienced DLT. All patients who were not evaluableTable 1. Dose Levels
Dose Level Clofarabine Dose Melphalan Dose
1 30 mg/m2 100 mg/m2
2 40 mg/m2 100 mg/m2
3 40 mg/m2 140 mg/m2for toxicity were replaced. No dosage escalation oc-
curred until both GR and DLT evaluations were
complete on all patients at a dose level.
We adopted the simulation approach of Gooley
et al. [17]. For this group of patients, who are at ex-
treme risk for relapse, we were willing to accept
a DLT rate as high as 20% and a GR rate of 5%,
with 3 dosage levels to be tested. In particular, we
chose a design with the following operating character-
istics: a 14% chance of finding that the drug combina-
tion lacked safety when the GR rate ranged from 5%
(dose level 1) to 2% (dose levels 2 and 3) and the
DLT rate ranged from 5% (dose level 1) to 15%
(dose level 2) to 20% (dose level 3). With GR rates in-
creased to 25%, 20%, and 20% for dose levels 1-3, re-
spectively, the probability of declaring that the drug
combination lacked safety was 73% during the dose-
finding study. The specific decision rules were based
on a modified 3 1 3 design, with escalation and dees-
calation decisions designed to achieve the operating
characteristics as described above.
Correlative Studies
Tomeasure immune reconstitution after treatment,
peripheral blood samples were obtained from patients
at defined time intervals on days 0, 114, 130, 160,
and 1100, and 6 months posttransplantation. Periph-
eral blood mononuclear cells were isolated from blood
samples and directly stained without cryopreservation,
using panels of fluorescently conjugated antibodies to
identify the following leukocyte subsets: monocytes
(CD451, CD141), helper T lymphocytes (CD31,
CD41, CD451), cytotoxic T lymphocytes (CD31,
CD81, CD451), natural killer (NK) cells (CD451,
CD32, CD161, CD561), NK T cells (CD451,
CD31, CD161, CD561), immature B cells (CD451,
CD51, CD191), and mature B cells (CD451, CD52,
CD191). A primary leukocyte gate was set on CD451
cells and a secondary lymphocyte gate was set on
CD142 cells, and each of the foregoing subsets was de-
termined as a percentage of leukocytes. Absolute counts
of each cell subset were determined using TruCOUNT
beads (BD Biosciences, San Jose, CA). Data were
acquired using a Gallios flow cytometer (Beckman
Coulter, Brea, CA) and analyzed using FCS Express
version 3.0 software (De Novo Software, Los Angeles,
CA).RESULTS
Patient Characteristics
A total of 18 adult patients were enrolled in the
study between October 2007 and May 2010. Two en-
rolled patients were determined to be ineligible: 1 pa-
tient because of preexisting typhlitis and 1 patient due
to a double-HLA mismatch. These patients were
Table 2. Patient Characteristics
Age at transplantation, years, median (range) 62.8 (30.5-65.7)
Sex, n (%)
Female 9 (56)
Male 7 (44)
Donor relation, n (%)
Sibling donor 8 (50)
Matched unrelated donor 8 (50)
Cytogenetic risk group, n (%)*
Favorable 1 (6)
Intermediate 6 (38)
Unfavorable 9 (56)
Disease status at transplantation, n (%)
CR1 7 (44)
First relapse 3 (19)
CR2 2 (12)
Induction failure 4 (25)
Stem cell source, n (%)
Bone marrow 1 (6)
Peripheral blood 15 (94)
*Cytogenetic risk group according to the scheme of Slovak et al. [18].
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16 eligible patients with AML (7 males and 9 females;
median age, 63 years; age range, 30-66 years) were
treated in this study; their characteristics are summa-
rized in Table 2. Seven patients were in CR1 at the
time of transplantation, 2 were in CR2, 4 had primary
induction failure, and 3 were in first relapse. Overall, of
the 16 eligible patients, 9 had unfavorable cytogenet-
ics, 6 had intermediate cytogenetics, and 1 had favor-
able cytogenetics at the time of study entry, based on
the criteria of Slovak et al. [18]. Of the 7 patients in
CR1, 4 had unfavorable cytogenetics and 3 had inter-
mediate cytogenetics.Treatment and Toxicities
Grade III nonhematologic toxicities included ele-
vated transaminase levels, diarrhea, and hyponatremia.
No DLTs were seen in the 3 patients treated at dose
level 1. One patient at dose level 2 died before engraft-
ment due to hepatic, renal, and infectious toxicities; in
response, dose level 2 was expanded for safety pur-
poses, and no further DLTs occurred. The first patient
treated at dose level 3 developed multiorgan failureTable 3. Bearman Toxicities
Adverse Event
Dose Level 1 (n 5 3)
Grade I Grade II Grade I
Bladder toxicity 1
CNS toxicity (stroke)
Cardiac toxicity
GI toxicity 8
Hepatic toxicity 1 2 7
Pulmonary toxicity 1
Renal toxicity 1
Stomatitis 2 6
*Same patient; patient died from multiorgan failure before engraftment.
†Same patient; patient died from multiorgan failure before engraftment.and died before engraftment. Given that dose level 3
involved an increase in the melphalan dose alone,
and that excellent results were seen in the 2 previous
cohorts with the maximum study dose of clofarabine,
the decision was made to not enroll any more patients
on dose level 3, but rather to further expand dose level
2 to 12 patients (clofarabine 40 mg/m2 and melphalan
100 mg/m2). Table 3 shows the Bearman toxicities for
patients at each dose level. Tables 4 and 5 present
engraftment and GVHD data. Additional Common
Terminology Criteria for Adverse Events 3.0
toxicities (other than fatigue and reversible electrolyte
abnormalities) not captured by the Bearman scale and
the engraftment and GVHD summaries include grade
3 headache (n 5 2), grade 3 hypertension (n 5 2),
grade 3 vascular access–related thrombosis (n 5 1),
and grade 3 anal/vaginal pain (n 5 1).Outcomes
Engraftment
All 14 evaluable patients engrafted successfully.
The median time to ANC recovery (the first of 3 con-
secutive days with ANC $0.5  109/L) was 14 days,
and that to platelet recovery was 16 days (7 days post-
transfusion, and the first of 3 consecutive days of plate-
let count $20  109/L). Three patients with primary
induction failure received an unrelated donor graft
and subsequently achieved complete engraftment and
remission. Time to engraftment for each patient is
shown in Table 4.
Immune Reconstitution
Correlative studies were performed to determine
the rate of immune reconstitution of various hemato-
poietic cell types. Figure 2 shows mean values of
WBCs, cytotoxic T lymphocytes, helper T lympho-
cytes, NK cells, and B cells from 15 patients measured
from the time of transplantation to 180 days posttrans-
plantation. Leukocyte subsets corresponding to imma-
ture B cells and NK T cells were also evaluated and
found only at low levels (data not shown). The meanDose Level 2 (n 5 12) Dose Level 3 (n 5 1)
Grade II Grade III Grade IV Grade IV
1
1†
1*
4 1*
1†
1 1* 1†
1*
Table 4. Patient Outcomes at Each Dose Level
Dose
Level Patient Donor Disease Status
Cytogenetic
Risk [18]
Days to
ANC $500*
Days to
PLT $20*
Chimerism
% PB/Marrow
Follow-Up,
Months† Status
1 1 R CR2 Intermediate 15 15 100/NA 35.0 Remission
1 2 R CR2 Favorable 14 14 100/100 33.5 Remission
1 3 R CR1 Unfavorable 24 17 100/100 32.5 Remission
2 4‡ R First relapse Intermediate Died day 23 0.8 Died at day 23
2 5 R CR1 Intermediate 13 14 NA/100 29.3 Remission
2 6 U IF Unfavorable 17 16 NA/100 18.7 Remission
2 7 U CR1 Unfavorable 12 16 NA/98 22.7 Remission
2 8 R CR1 Unfavorable 16 15 96/97 14.8 Remission
2 9 R CR1 Intermediate 11 15 100/99 7.3 Related; died at day 223
2 10 U First relapse Intermediate 16 13 100/100 6.6 Died at day 200; CNS bleed
2 11 U CR1 Intermediate 13 18 NA/100 11.9 Remission
3 12‡ U Induction failure Unfavorable Died day 12 0.4 Died at day 12
2 13 R Induction failure Unfavorable 13 15 100/99.4 8.5 Remission
2 14 U CR1 Unfavorable 12 15 99.6/99.6 8.8 Relapse at 8.8 months
2 15 U Induction failure Unfavorable 14 16 100/99.9 8.0 Remission
2 16 U First relapse Unfavorable 14 36 99.9/99.9 4.3 Remission
Median 14 15
NA indicates not available; PB, peripheral blood; R, related; U, unrelated.
Patients are listed in the order of accrual.
*Days from transplantation. Following Center for International Blood and Marrow Transplant Research rules (Form 2450 instructions, version 1/25/
2010) for 7 days since last platelet transfusion and first of 3 consecutive days with >20,000 platelets per microliter blood.
†Days from transplantation to relapse/death or last contact.
‡Patient died before engraftment.
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and helper T lymphocytes were at the lower end of
the range seen in normal donors within approximately
30 days posttransplantation.
GVHD
Five patients had mild acute GVHD of the skin.
4 patients had mild chronic GVHD, and 1 patient de-
veloped severe chronic GVHD of the liver and died
at day 201 posttransplantation from a CNS bleed
due to tacrolimus-sirolimus–related transplantation-
associated thromboticmicroangiopathy. The incidence
of GVHD is presented in Table 5.Table 5. GVHD Incidence
Type n (%)
Acute GVHD
Grade 0 9 (56)
Grade I 3 (19)
Grade II 4 (25)
Skin acute GVHD
Grade 0 11 (69)
Grade I 1 (6)
Grade II 3 (19)
Grade III 1 (6)
Lower GI acute GVHD
Grade 0 14 (88)
Grade I 2 (12)
Upper GI acute GVHD
Grade 0 16 (100)
Liver acute GVHD
Grade 0 16 (100)
Chronic GVHD
No 9 (56)
Yes 5 (31)
< 100 days of follow-up 2 (13)Treatment Response
Although not a primary endpoint of this study, the
treatment responses of the 16 patients were followed
and are shown in Table 4. Of the 14 patients who com-
pleted transplantation, only 2 patients relapsed. The
median follow-up of the 12 patients alive at the date
of analysis was 16.8 months (range, 4.3-35.0 months).
Survival
Both overall survival (OS) and event-free survival
(EFS; with death and relapse as events) were estimated
from the day of transplantation for the 12 patients
treated on the recommended phase II dose
(Figure 3). OS point estimates at 6 months were 92%
(95% confidence interval [CI], 54%-99%) at 6 months
and 73% (95% CI, 38%-91%) at 1 year. Estimated
EFS was 83% (95% CI, 46%-95%) at 6 months and
61% (95% CI, 26%-84%) at 1 year.DISCUSSION
Reduced-intensity allogeneic transplantation regi-
mens were introduced to achieve 2 major goals. The
primary therapeutic goal is to achieve engraftment,
based on the idea that the immune activity of the in-
fused allogeneic cells should be effective in eliminating
tumor cells in the recipient [6]. The second goal is to
reduce the incidence of non–relapse-related toxicities
caused by the high chemotherapy doses previously
thought to be necessary to ensure engraftment in the
myeloablative setting. With a reduction of overall tox-
icity, this potentially curative modality for leukemia is
more applicable in the older patient population, which
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Figure 2. Reconstitution of immune cell subsets. Mean cell numbers are plotted for 15 patients. Error bars indicate standard error. Subsets were de-
fined as follows: CD4 T cells (CD31, CD451, CD41), CD8 T cells (CD31, CD451, CD81), NK cells (CD451, CD32, CD161, CD561), B cells
(CD451, CD52, CD191). Dotted lines represent the upper and lower ranges of normal values.
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With the introduction of fludarabine-based condition-
ing regimens, the goal of reducing transplantation-
related mortality appears to have been achieved, and
this approach is in widespread use [6,19]. Clearly,
however, the ability to achieve both goals of
reduced-intensity conditioning using a regimen with0 6 12 18 24 30
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Figure 3. OS and EFS estimates for the 12 patients at dose level 2
(clofarabine 40 mg/m2 and melphalan 100 mg/m2), who had a median
follow-up time of 16.8 months.greater intrinsic antileukemia activity without signifi-
cantly greater toxicity is desirable.
One significant advantage of using clofarabine in
the conditioning regimen is that, aside from the po-
tential gains in immunosuppression, the drug has
increased activity against leukemias. In the initial
phase I study conducted at M.D. Anderson Cancer
Center, the maximum tolerated dose was established
as 40 mg/m2 daily for 5 days, and the DLT was hepa-
totoxicity, which was seen at a dose of 55 mg/m2. That
study included all acute leukemias; there was an objec-
tive response rate of 16%, with 2 patients in CR (in 1
patient with AML and 1 patient with ALL) and an-
other 2 patients in CR without platelet recovery
(CRp; in 1 patient with AML and 1 patient with
ALL) [20]. In a phase II study of 112 eligible patients
with untreated AML who were $60 years old, using
the 40 mg/m2 dose for 5 days, 51 patients achieved
CR or CRp, for an overall response rate of 46% and
a median OS of 41 weeks for the group, 72 weeks for
those achieving CR, and 59 weeks for those achieving
CR or CRp. The most frequent toxicities seen in that
study were hyperbilirubinemia and transaminitis
(which returned to baseline after a median of 15
438 Biol Blood Marrow Transplant 18:432-440, 2012M. H. Kirschbaum et al.days), along with rashes, pruritis, andmucositis [21]. In
a report of 2 European studies of clofarabine as upfront
monotherapy in patients with untreated AML who
were $60 years old, of 106 patients, 32% had CR
and an additional 16% had CR with incomplete pe-
ripheral blood count recovery [22].
In the present study, we combined clofarabine and
melphalan, starting at relatively low doses of both
agents, with dose-escalation guidelines built into the
study in the event that patients did not achieve stable
engraftment. However, the first 3 patients, who
received only clofarabine 30 mg/m2 and melphalan
100 mg/m2, engrafted rapidly and remained in remis-
sion for more than 30 months. All 3 of these patients
received a matched sibling transplant and were treated
with the GVHD prophylaxis regimen (cyclosporine/
mycophenolate) that was standard at the time. Further
studies on the use of that dosage schedule in recipients
of unrelated transplants are needed. At the time of
initiation of dose level 2 (clofarabine 40 mg/m2 and
melphalan 100 mg/m2), the institutional policy
had changed to the use of tacrolimus/sirolimus as
GVHD prophylaxis. At this dose level, 7 patients
underwent transplantation with a matched unrelated
donor, and all 7 achieved complete chimerism at
a rate similar to those who underwent transplantation
with a sibling donor. Only fully matched donors were
eligible for this study. Further studies are needed to de-
termine the safety of this regimen in transplant
recipients with mismatched donors, perhaps with the
addition of antithymocyte globulin, as was done in
a similar study combining clofarabine plus fludarabine
as the allogeneic transplantation conditioning regimen,
which included an arm of clofarabine plus busulfan [23].
In terms of toxicities, transplantations performed
using this regimen were well tolerated despite the rel-
atively older age of the patients. Of note is the minimal
amount of stomatitis and veno-occlusive disease seen
at any of the three dose levels. The transient transam-
inase elevations seen with clofarabine did not seem to
translate into hepatic toxicities overall, and the ele-
vated transaminase levels mostly resolved early. There
were only 2 transplantation-related deaths at dose
levels 1 and 2, including 1 early death at dose level 2
attributed to conditioning and 1 death due to CNS
bleed at day 200 in a patient who had fully engrafted.
The first patient enrolled in dose level 3 (melphalan
140 mg/m2 and clofarabine 40 mg/m2) died early of
complications attributed to conditioning. Because
the objective of engraftment had been satisfactorily
achieved at the first 2 dose levels, we decided to not
accrue any more patients to dose level 3 and instead
expanded dose level 2. Given that dose level 3 was an
increase in melphalan alone, and that we had seen ex-
cellent results at the 2 previous dose levels with the
maximum dose of clofarabine achieved, we decided
to end enrollment in dose level 3, because continuedaccrual at this dose level posed an unnecessary risk to
the patients. Despite technically not reaching the ob-
jective of the maximum tolerated dose for melphalan,
we did not feel that the risk–benefit ratio supported
subjecting additional patients to a potentially toxic
combination, when it was clear that the goal of engraft-
ment was reached and time to progression appeared to
be at least no worse than that for other transplantation
regimens. As a result, we cannot formally establish the
maximum tolerated dose of the combination of mel-
phalan and clofarabine.
GVHD was relatively mild in the patients treated
with this regimen, with almost all episodes of acute
GVHD limited to the skin and only 1 case of grade
III skin GVHD. In all cases, acute skin GVHD re-
sponded rapidly to standard therapy. There were no
cases of upper gastrointestinal (GI) or liver involve-
ment. Given that the primary objective of the study
was to determine engraftment, assessment of chronic
GVHD was limited; however, at the time of this re-
port, fewer than one-half of the patients had any
chronic GVHD, and all cases thus far have been mild.
Immune reconstitution after hematopoietic stem
cell transplantation occurs progressively [24], with
NK cells recovering rapidly during the first few weeks
after transplantation, reaching supranormal levels at
1-3 months posttransplantation. In contrast, recovery
of CD41 and CD81 T cells requires several months,
and recovery of CD4 T cells takes more than 1 year.
It is generally accepted that recovery of the T cell com-
partment is initially dependent on expansion of mem-
ory T cells in the periphery, driven by cytokines and
antigens, before thymic production of na€ıve T cells
can start [25]. The literature is divided on the impact
of the intensity of conditioning on posttransplantation
immune reconstitution. Some studies have reported
no differences between reduced-intensity and my-
eloablative conditioning regimens [26-30], whereas
others have reported more rapid T lymphocyte
recovery in patients with reduced-intensity condition-
ing [31-34]. B cell reconstitution is also slow, taking
approximately a year to reach normal levels, even in
patients undergoing reduced-intensity transplanta-
tion, and is markedly influenced by conditioning
[35]. In a subset of our patients, we analyzed immune
reconstitution by flow cytometry, using the cell surface
markers shown in Figure 2. Although our study did not
include a control group of patients who received flu-
darabine instead of clofarabine, comparing our flow
cytometry data with published results suggests greater
similarity in initial suppression and reconstitution after
a more intense regimen, particularly with regard to
CD4T cells andNK cells. Thus, clofarabine may offer
the alternative of a deeper immunosuppressive regi-
men but without the overall toxicities seen with the
older myeloablative regimens. It is noteworthy that
complete engraftment was seen with both dosage
Biol Blood Marrow Transplant 18:432-440, 2012 439Phase I Clofarabine/Melphalan Allo Transplantlevels of clofarabine, suggesting the possibility of phase
II studies at either dose level for matched related trans-
plantations. In the 30-mg/m2 cohort, no unrelated do-
nor transplantations were performed; however, all
unrelated matched donor transplants were successfully
engrafted at the 40-mg/m2 dose level.
Although progression-free survival was not a for-
mal objective of this study and the follow-up was rela-
tively brief, it is noteworthy that few relapses occurred,
despite the large number of patients beyond CR1,
including 7 patients with active disease either in first
relapse or primary induction failure. Of the 7 patients
who underwent transplantation with active disease,
2 died of conditioning-related toxicity and 1 died of
a CNS bleed at day 200, whereas the others remained
in remission posttransplantation. Overall, 2 patients
relapsed, both of whom underwent transplantation in
CR1, at 7 months and 9 months posttransplantation.
This promising outcome in older patients with high-
risk or active disease suggests that a randomized trial
against standard fludarabine plus melphalan condi-
tioning regimens would be of value in optimizing
transplantation alternatives for this patient population.ACKNOWLEDGMENTS
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